Novartis Snaps Up Cachexia Candidate On The Cheap As AVEO's Focus Returns to Tivozanib

AVEO Oncology is seeing the resurgence in its fortunes continue with the signing of a licensing agreement with Novartis for its growth differentiation factor 15 (GDF15) inhibitory antibody AV-380, which is in preclinical development as a potential treatment for cachexia.